Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad

77
7
Favorite

Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad

Motley Fool2021-07-27

When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（7）

TonySiang
·2021-07-27
Hmmm.....
Reply
1
Report
大笨象形
·2021-07-27
[無語] [無語] [憤怒] [鬼臉] [鬼臉] [鬼臉] [噴血] [齜牙] [笑哭] [鬼臉] [難過] [齜牙] [可愛] [難過] [齜牙] [笑哭] [鬼臉] [鬼臉]
Reply
1
Report
MightyPooP
·2021-07-27
It's the most sought after vaccine here at the moments.
Reply
3
Report
LohYK
·2021-07-27
It's already a record to come out with a vaccine so fast. Dun complain
Reply
3
Report
SharonStone
·2021-07-27
Huh.....
Reply
3
Report
Fold Replies
- Fatboy79:
  Not even fIt to be called vaccine
  2021-07-27
  Reply
  Report
慢的老人
·2021-07-27
All vaccines require booster shots. It is nothing unusual.
Reply
6
Report
Fold Replies
- MightyPooP:
  yup
  2021-07-27
  Reply
  Report
Jasonngui
·2021-07-27
?
Reply
4
Report
Fold Replies
- Jasonngui:
  Sad[Facepalm]
  2021-07-27
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2154395259?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-27 10:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2154395259","market":"us","top_or_hot":-1,"title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","media":"Motley Fool","content":"<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NWS","symbol_name":"新闻集团","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","article_id":"2154395259","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","pubTimestamp":1627354680,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"All eyes are on Pfizer versus the delta variant.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"translate_title":"这就是为什么关于辉瑞疫苗的坏消息并不那么坏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NWS":0.9,"PFE":0.9},"content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":809854106,"gmtCreate":1627360184505,"gmtModify":1703488366833,"author":{"id":"3581932790709378","authorId":"3581932790709378","name":"TonySiang","avatar":"https://static.tigerbbs.com/8cb5d434f44a3592cfa411ef91eeb408","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581932790709378","authorIdStr":"3581932790709378"},"htmlText":"Hmmm.....","listText":"Hmmm.....","text":"Hmmm.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809854106","repostId":2154395259,"repostType":4,"repost":{"id":"2154395259","pubTimestamp":1627354680,"share":"https://ttm.financial/m/news/2154395259?lang=&edition=fundamental","pubTime":"2021-07-27 10:58","market":"us","language":"en","title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","media":"Motley Fool","summary":"All eyes are on Pfizer versus the delta variant.","content":"<p>When we think of the <b>Pfizer</b> (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.</p>\n<p>Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.</p>\n<h2>A drop in coronavirus prevention</h2>\n<p>First, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.</p>\n<p>Here's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.</p>\n<p>But here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.</p>\n<p>Next, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.</p>\n<h2>Vaccine efficacy or declining immunity?</h2>\n<p>So, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.</p>\n<p>This matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.</p>\n<p>And this isn't a detail unique to Pfizer. Rival vaccine maker <b>Moderna</b> also has spoken of the necessity of a booster in about the same timeframe.</p>\n<p>This brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.</p>\n<p>Pfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.</p>\n<h2>An extra $1.7 billion</h2>\n<p>If it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.</p>\n<p>Of course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.</p>\n<p>This movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154395259","content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809839686,"gmtCreate":1627356537745,"gmtModify":1703488286783,"author":{"id":"4087977377718970","authorId":"4087977377718970","name":"大笨象形","avatar":"https://static.tigerbbs.com/027c1a6287834dfcfa71829d2b6d94b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087977377718970","authorIdStr":"4087977377718970"},"htmlText":"[無語]&nbsp;[無語]&nbsp;[憤怒]&nbsp;[鬼臉]&nbsp;[鬼臉]&nbsp;[鬼臉]&nbsp;[噴血]&nbsp;[齜牙]&nbsp;[笑哭]&nbsp;[鬼臉]&nbsp;[難過]&nbsp;[齜牙]&nbsp;[可愛]&nbsp;[難過]&nbsp;[齜牙]&nbsp;[笑哭]&nbsp;[鬼臉]&nbsp;[鬼臉]&nbsp;","listText":"[無語]&nbsp;[無語]&nbsp;[憤怒]&nbsp;[鬼臉]&nbsp;[鬼臉]&nbsp;[鬼臉]&nbsp;[噴血]&nbsp;[齜牙]&nbsp;[笑哭]&nbsp;[鬼臉]&nbsp;[難過]&nbsp;[齜牙]&nbsp;[可愛]&nbsp;[難過]&nbsp;[齜牙]&nbsp;[笑哭]&nbsp;[鬼臉]&nbsp;[鬼臉]&nbsp;","text":"[無語] [無語] [憤怒] [鬼臉] [鬼臉] [鬼臉] [噴血] [齜牙] [笑哭] [鬼臉] [難過] [齜牙] [可愛] [難過] [齜牙] [笑哭] [鬼臉] [鬼臉]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809839686","repostId":2154395259,"repostType":4,"repost":{"id":"2154395259","pubTimestamp":1627354680,"share":"https://ttm.financial/m/news/2154395259?lang=&edition=fundamental","pubTime":"2021-07-27 10:58","market":"us","language":"en","title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","media":"Motley Fool","summary":"All eyes are on Pfizer versus the delta variant.","content":"<p>When we think of the <b>Pfizer</b> (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.</p>\n<p>Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.</p>\n<h2>A drop in coronavirus prevention</h2>\n<p>First, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.</p>\n<p>Here's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.</p>\n<p>But here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.</p>\n<p>Next, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.</p>\n<h2>Vaccine efficacy or declining immunity?</h2>\n<p>So, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.</p>\n<p>This matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.</p>\n<p>And this isn't a detail unique to Pfizer. Rival vaccine maker <b>Moderna</b> also has spoken of the necessity of a booster in about the same timeframe.</p>\n<p>This brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.</p>\n<p>Pfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.</p>\n<h2>An extra $1.7 billion</h2>\n<p>If it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.</p>\n<p>Of course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.</p>\n<p>This movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154395259","content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":809897250,"gmtCreate":1627356433170,"gmtModify":1703488283664,"author":{"id":"3575163551534398","authorId":"3575163551534398","name":"MightyPooP","avatar":"https://static.tigerbbs.com/aec66d00ca2b1f2b75412008d93edd14","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":1,"idStr":"3575163551534398","authorIdStr":"3575163551534398"},"htmlText":"It's the most sought after vaccine here at the moments.&nbsp;","listText":"It's the most sought after vaccine here at the moments.&nbsp;","text":"It's the most sought after vaccine here at the moments.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809897250","repostId":2154395259,"repostType":4,"repost":{"id":"2154395259","pubTimestamp":1627354680,"share":"https://ttm.financial/m/news/2154395259?lang=&edition=fundamental","pubTime":"2021-07-27 10:58","market":"us","language":"en","title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","media":"Motley Fool","summary":"All eyes are on Pfizer versus the delta variant.","content":"<p>When we think of the <b>Pfizer</b> (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.</p>\n<p>Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.</p>\n<h2>A drop in coronavirus prevention</h2>\n<p>First, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.</p>\n<p>Here's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.</p>\n<p>But here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.</p>\n<p>Next, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.</p>\n<h2>Vaccine efficacy or declining immunity?</h2>\n<p>So, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.</p>\n<p>This matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.</p>\n<p>And this isn't a detail unique to Pfizer. Rival vaccine maker <b>Moderna</b> also has spoken of the necessity of a booster in about the same timeframe.</p>\n<p>This brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.</p>\n<p>Pfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.</p>\n<h2>An extra $1.7 billion</h2>\n<p>If it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.</p>\n<p>Of course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.</p>\n<p>This movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154395259","content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809891172,"gmtCreate":1627356108996,"gmtModify":1703488274365,"author":{"id":"3568070265339857","authorId":"3568070265339857","name":"LohYK","avatar":"https://static.tigerbbs.com/d6add0343094f5e965e831fa432314ef","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":8,"crmLevelSwitch":1,"idStr":"3568070265339857","authorIdStr":"3568070265339857"},"htmlText":"It's already a record to come out with a vaccine so fast. Dun complain","listText":"It's already a record to come out with a vaccine so fast. Dun complain","text":"It's already a record to come out with a vaccine so fast. Dun complain","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809891172","repostId":2154395259,"repostType":4,"repost":{"id":"2154395259","pubTimestamp":1627354680,"share":"https://ttm.financial/m/news/2154395259?lang=&edition=fundamental","pubTime":"2021-07-27 10:58","market":"us","language":"en","title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","media":"Motley Fool","summary":"All eyes are on Pfizer versus the delta variant.","content":"<p>When we think of the <b>Pfizer</b> (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.</p>\n<p>Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.</p>\n<h2>A drop in coronavirus prevention</h2>\n<p>First, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.</p>\n<p>Here's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.</p>\n<p>But here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.</p>\n<p>Next, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.</p>\n<h2>Vaccine efficacy or declining immunity?</h2>\n<p>So, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.</p>\n<p>This matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.</p>\n<p>And this isn't a detail unique to Pfizer. Rival vaccine maker <b>Moderna</b> also has spoken of the necessity of a booster in about the same timeframe.</p>\n<p>This brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.</p>\n<p>Pfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.</p>\n<h2>An extra $1.7 billion</h2>\n<p>If it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.</p>\n<p>Of course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.</p>\n<p>This movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154395259","content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809805802,"gmtCreate":1627355771206,"gmtModify":1703488266850,"author":{"id":"3585277181858248","authorId":"3585277181858248","name":"SharonStone","avatar":"https://static.tigerbbs.com/93087f864e3179c2f8d0c05b66c6fb5e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585277181858248","authorIdStr":"3585277181858248"},"htmlText":"Huh.....&nbsp;","listText":"Huh.....&nbsp;","text":"Huh.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809805802","repostId":2154395259,"repostType":4,"repost":{"id":"2154395259","pubTimestamp":1627354680,"share":"https://ttm.financial/m/news/2154395259?lang=&edition=fundamental","pubTime":"2021-07-27 10:58","market":"us","language":"en","title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","media":"Motley Fool","summary":"All eyes are on Pfizer versus the delta variant.","content":"<p>When we think of the <b>Pfizer</b> (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.</p>\n<p>Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.</p>\n<h2>A drop in coronavirus prevention</h2>\n<p>First, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.</p>\n<p>Here's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.</p>\n<p>But here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.</p>\n<p>Next, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.</p>\n<h2>Vaccine efficacy or declining immunity?</h2>\n<p>So, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.</p>\n<p>This matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.</p>\n<p>And this isn't a detail unique to Pfizer. Rival vaccine maker <b>Moderna</b> also has spoken of the necessity of a booster in about the same timeframe.</p>\n<p>This brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.</p>\n<p>Pfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.</p>\n<h2>An extra $1.7 billion</h2>\n<p>If it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.</p>\n<p>Of course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.</p>\n<p>This movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154395259","content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5342350,"gmtCreate":1627356249411,"gmtModify":1663231553127,"authorId":3560390730639874,"author":{"id":3560390730639874,"idStr":"3560390730639874","authorId":3560390730639874,"name":"Fatboy79","avatar":"https://static.tigerbbs.com/f550c98b42b2fd97e2989fbf50af5b9b","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.11%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809805802,"type":1,"supId":0,"prevId":0,"content":"Not even fIt to be called vaccine","text":"Not even fIt to be called vaccine","html":"Not even fIt to be called vaccine"}],"langContent":"EN"},{"id":809809736,"gmtCreate":1627355430025,"gmtModify":1703488259362,"author":{"id":"3582028884093480","authorId":"3582028884093480","name":"慢的老人","avatar":"https://static.tigerbbs.com/d8809bb976396889eb133162af0901b8","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3582028884093480","authorIdStr":"3582028884093480"},"htmlText":"All vaccines require booster shots. It is nothing unusual.&nbsp;","listText":"All vaccines require booster shots. It is nothing unusual.&nbsp;","text":"All vaccines require booster shots. It is nothing unusual.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809809736","repostId":2154395259,"repostType":4,"repost":{"id":"2154395259","pubTimestamp":1627354680,"share":"https://ttm.financial/m/news/2154395259?lang=&edition=fundamental","pubTime":"2021-07-27 10:58","market":"us","language":"en","title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","media":"Motley Fool","summary":"All eyes are on Pfizer versus the delta variant.","content":"<p>When we think of the <b>Pfizer</b> (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.</p>\n<p>Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.</p>\n<h2>A drop in coronavirus prevention</h2>\n<p>First, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.</p>\n<p>Here's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.</p>\n<p>But here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.</p>\n<p>Next, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.</p>\n<h2>Vaccine efficacy or declining immunity?</h2>\n<p>So, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.</p>\n<p>This matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.</p>\n<p>And this isn't a detail unique to Pfizer. Rival vaccine maker <b>Moderna</b> also has spoken of the necessity of a booster in about the same timeframe.</p>\n<p>This brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.</p>\n<p>Pfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.</p>\n<h2>An extra $1.7 billion</h2>\n<p>If it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.</p>\n<p>Of course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.</p>\n<p>This movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154395259","content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5342396,"gmtCreate":1627356478361,"gmtModify":1663231553137,"authorId":3575163551534398,"author":{"id":3575163551534398,"idStr":"3575163551534398","authorId":3575163551534398,"name":"MightyPooP","avatar":"https://static.tigerbbs.com/aec66d00ca2b1f2b75412008d93edd14","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809809736,"type":1,"supId":0,"prevId":0,"content":"<u>yup</u>","text":"<u>yup</u>","html":"<u>yup</u>"}],"langContent":"EN"},{"id":809175889,"gmtCreate":1627355244741,"gmtModify":1703488253861,"author":{"id":"3581937655679729","authorId":"3581937655679729","name":"Jasonngui","avatar":"https://static.tigerbbs.com/4257d49eb28e662a88192e8c09a3ffaf","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581937655679729","authorIdStr":"3581937655679729"},"htmlText":"?&nbsp;","listText":"?&nbsp;","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809175889","repostId":2154395259,"repostType":4,"repost":{"id":"2154395259","pubTimestamp":1627354680,"share":"https://ttm.financial/m/news/2154395259?lang=&edition=fundamental","pubTime":"2021-07-27 10:58","market":"us","language":"en","title":"Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad","url":"https://stock-news.laohu8.com/highlight/detail?id=2154395259","media":"Motley Fool","summary":"All eyes are on Pfizer versus the delta variant.","content":"<p>When we think of the <b>Pfizer</b> (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.</p>\n<p>Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.</p>\n<h2>A drop in coronavirus prevention</h2>\n<p>First, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.</p>\n<p>Here's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.</p>\n<p>But here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.</p>\n<p>Next, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.</p>\n<h2>Vaccine efficacy or declining immunity?</h2>\n<p>So, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.</p>\n<p>This matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.</p>\n<p>And this isn't a detail unique to Pfizer. Rival vaccine maker <b>Moderna</b> also has spoken of the necessity of a booster in about the same timeframe.</p>\n<p>This brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.</p>\n<p>Pfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.</p>\n<h2>An extra $1.7 billion</h2>\n<p>If it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.</p>\n<p>Of course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.</p>\n<p>This movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why the Bad News About the Pfizer Vaccine Isn't So Bad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NWS":"新闻集团","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/26/this-bad-news-may-equal-more-pfizer-revenue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154395259","content_text":"When we think of the Pfizer (NYSE:PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial.\nPfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel. And speaking of Israel, the country announced news last week that paints another picture of the Pfizer vaccine's effectiveness. This may seem like bad news on the surface. But it might not be all that negative. And it actually may lead to more revenue for Pfizer. Let's take a closer look.\nA drop in coronavirus prevention\nFirst, the news. The Pfizer vaccine's efficacy in overall coronavirus prevention declined to 39% during the one-month period ending July 17, according to Israel's Health Ministry. That's down from 64% in the period of June 6 through the early days of July. Effectiveness in severe disease is decreasing at a much slower rate. It's down to 91% from 93% in the earlier report. At the same time, the highly contagious delta variant is gaining ground.\nHere's why investors may initially worry: The numbers alone seem to say the vaccine isn't working well against today's coronavirus variants -- primarily delta. And that's enough reason for governments to think twice before ordering more Pfizer doses.\nBut here's why investors shouldn't worry. First, efficacy in preventing severe coronavirus remains extremely high. It would be great to prevent every coronavirus infection. But what's most important is preventing the worst infections and death. The Pfizer vaccine continues to do just that.\nNext, we have to look beyond the numbers. Israel launched a rapid and aggressive vaccine rollout early in the year. Many older people and those with comorbidities received vaccination in January. Six months down the road, it's likely immunity is waning.\nVaccine efficacy or declining immunity?\nSo, the issue we're facing may not be one of vaccine efficacy against the delta variant. Instead, it may simply be the issue of declining immunity. And this shouldn't be a surprise. Pfizer CEO Albert Bourla told CNBC a few months ago that a booster shot probably would be needed six to 12 months after initial vaccination. He even mentioned that variants may be a determining factor.\nThis matches the situation in Israel. Efficacy looked better there a few months ago when vaccination was more recent. Now, immunity has decreased over time, and variants have gotten tougher. So, the need for a booster is increasing.\nAnd this isn't a detail unique to Pfizer. Rival vaccine maker Moderna also has spoken of the necessity of a booster in about the same timeframe.\nThis brings me to how all of this could equal higher revenue for Pfizer. The situation in Israel looks like real world evidence that a booster is needed now or soon -- at least for people who were vaccinated earlier in the year. And that would apply to vaccinated individuals anywhere in the world.\nPfizer said this month that it plans on seeking regulatory authorization for a third dose of its vaccine to be given as a booster. Health leaders weren't immediately supportive of the idea. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention said around the same time as the Pfizer announcement that anyone who is fully vaccinated doesn't need a booster right now. But with cases quickly rising, that message could change sooner rather than later.\nAn extra $1.7 billion\nIf it does, Pfizer doses may fly off the shelves. If every American fully vaccinated with Pfizer so far opts for a booster, we're looking at more than 86 million vaccine doses. At the price the U.S. originally paid for Pfizer vaccines, that represents $1.7 billion.\nOf course, this doesn't mean the U.S. will order an extra $1.7 billion in doses right away. But as the current supply decreases, the country may be quick to replenish -- and stock up for the next round of vaccinations. We may see this happen not only in the U.S., but worldwide.\nThis movement will take some time. Any increase in orders and revenue may happen next year and into the future. But right now, it looks like the stage is being set for that outcome. That's good news for those seeking maximum protection from COVID-19 -- and good news for Pfizer and its investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5342203,"gmtCreate":1627355263365,"gmtModify":1663231551138,"authorId":3581937655679729,"author":{"id":3581937655679729,"idStr":"3581937655679729","authorId":3581937655679729,"name":"Jasonngui","avatar":"https://static.tigerbbs.com/4257d49eb28e662a88192e8c09a3ffaf","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809175889,"type":1,"supId":0,"prevId":0,"content":"Sad[Facepalm]","text":"Sad[Facepalm]","html":"Sad[Facepalm]"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":77,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}